Skip to main content
SpringerLink
Log in

Current status of cardiac transplantation and mechanical circulatory support

  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Cardiac transplantation and mechanical circulatory support are possible options for improving survival and quality of life in patients with isolated cardiac disease and end-stage heart failure. Transplantation is limited by donor availability but has a median survival of 10 years. Post-transplant immunosuppression is often transplant center dependent, but a tacrolimus and mycophenolate mofetil-based regimen may be preferred. Sirolimus may reduce the progression rate of transplant vasculopathy. There has been a trend toward continuous-flow left ventricular assist devices because of their increased durability and reduced size. A variety of surgical and percutaneous ventricular assist devices may be used as a bridge to decision on a patient’s candidacy for transplantation. Mechanical circulatory support as destination therapy has not been widely implemented because of poor device durability, but this is expected to change with newer devices. Mechanical circulatory support as a bridge to myocardial recovery has been successful only in a few patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Bolling SF, Pagani FD, Deeb GM, Bach DS: Intermediateterm outcome of mitral reconstruction in cardiomyopathy. J Thorac Cardiovasc Surg 1998, 115:381–386.

    Article  PubMed  CAS  Google Scholar 

  2. Wu AH, Aaronson KD, Bolling SF, et al.: Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol 2005, 45:381–387.

    Article  PubMed  Google Scholar 

  3. Mancini DM, Eisen H, Kussmaul W, et al.: Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991, 83:778–786.

    PubMed  CAS  Google Scholar 

  4. Hershberger RE, Nauman D, Walker TL, et al.: Care processes and clinical outcomes of continuous outpatient support with inotropes (COSI) in patients with refractory endstage heart failure. J Card Fail 2003, 9:180–187.

    Article  PubMed  Google Scholar 

  5. Hershberger RE, Starling RC, Eisen HJ, et al.: Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005, 352:2705–2713.

    Article  PubMed  CAS  Google Scholar 

  6. Mehra MR, Zucker MJ, Wagoner L, et al.: A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation. J Heart Lung Transplant 2005, 24:1297–1304.

    Article  PubMed  Google Scholar 

  7. Taylor DO, Edwards LB, Aurora P, et al.: Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult heart transplant report-2008. J Heart Lung Transplant 2008, 27:943–956.

    Article  PubMed  Google Scholar 

  8. Eisen HJ, Kobashigawa J, Keogh A, et al.: Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005, 24:517–525.

    Article  PubMed  Google Scholar 

  9. Mancini D, Pinney S, Burkhoff D, et al.: Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003, 108:48–53.

    Article  PubMed  CAS  Google Scholar 

  10. Kobashigawa JA, Miller LW, Russell SD, et al.: Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006, 6:1377–1386.

    Article  PubMed  CAS  Google Scholar 

  11. Chen JM, Russo MJ, Hammond KM, et al.: Alternate waiting list strategies for heart transplantation maximize donor organ utilization. Ann Thorac Surg 2005, 80:224–228.

    Article  PubMed  Google Scholar 

  12. Kobashigawa JA, Moriguchi JD, Laks H, et al.: Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 2005, 24:1736–1740.

    Article  PubMed  Google Scholar 

  13. Tanaka K, Li H, Curran PJ, et al.: Usefulness and safety of percutaneous coronary interventions for cardiac transplant vasculopathy. Am J Cardiol 2006, 97:1192–1197.

    Article  PubMed  Google Scholar 

  14. Frazier OH, Rose EA, Oz MC, et al.: Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation. J Thorac Cardiovasc Surg 2001, 122:1186–1195.

    Article  PubMed  CAS  Google Scholar 

  15. El-Banayosy A, Deng M, Loisance DY, et al.: The European experience of Novacor left ventricular assist (LVAS) therapy as a bridge to transplant: a retrospective multi-centre study. Eur J Cardiothorac Surg 1999, 15:835–841.

    Article  PubMed  CAS  Google Scholar 

  16. Aaronson KD, Eppinger MJ, Dyke DB, et al.: Left ventricular assist device therapy improves utilization of donor hearts. J Am Coll Cardiol 2002, 39:1247–1254.

    Article  PubMed  Google Scholar 

  17. Pagani FD, Long JW, Dembitsky WP, et al.: Improved mechanical reliability of the HeartMate XVE left ventricular assist system. Ann Thorac Surg 2006, 82:1413–1418.

    Article  PubMed  Google Scholar 

  18. Miller LW, Pagani FD, Russell SD, et al.: Use of a continuous- flow device in patients awaiting heart transplantation. N Engl J Med 2007, 357:885–896.

    Article  PubMed  CAS  Google Scholar 

  19. Russell SD, Dyke DB, Aranda JM, et al.: Renal and hepatic function improve in advanced heart failure patients during continuous flow support with the HeartMate II LVAD [abstract 144]. Presented at the 11th Annual Scientific Meeting of the Heart Failure Society of America. Washington DC; September 16–19, 2007.

  20. Boyle AJ, Griffith B, Ascheim D, et al.: The VentrAssist LVAD as a bridge to cardiac transplantation: results on the US feasibility trial [abstract 518]. Presented at the International Society of Heart and Lung Transplantation 28th Annual Meeting and Scientific Sessions. Boston, MA; April 9–12, 2008.

  21. Kirklin JK, Naftel DC, Stevenson LW, et al.: INTERMACS database for durable devices for circulatory support: first annual report. J Heart Lung Transplant 2008, 27:1065–1072.

    Article  PubMed  Google Scholar 

  22. Lietz K, Long JW, Kfoury AG, et al.: Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era. Circulation 2007, 116:497–505.

    Article  PubMed  Google Scholar 

  23. Boyle AJ, Teuteberg JJ, Ascheim D, et al.: LVADs for less acutely ill patients: do current data justify the strategy? Presented at the 54th American Society of Artificial Internal Organs Annual Conference. San Francisco, CA; June 19–21, 2008.

  24. John R, Liao K, Lietz K, et al.: Experience with the Levitronix CentriMag circulatory support system as a bridge to decision in patients with refractory acute cardiogenic shock and multisystem organ failure. J Thorac Cardiovasc Surg 2007, 134:351–358.

    Article  PubMed  Google Scholar 

  25. Burkhoff D, Cohen H, Brunckhorst C, et al.: A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J 2006, 152:469.e1–469.e8.

    Article  Google Scholar 

  26. Henriques JP, Remmelink M, Baan J Jr, et al.: Safety and feasibility of elective high-risk percutaneous coronary intervention procedures with left ventricular support of the Impella Recover LP 2.5. Am J Cardiol 2006, 97:990–992.

    Article  PubMed  Google Scholar 

  27. Greenberg B, Czerska B, Delgado RM, et al.: Effects of continuous aortic flow augmentation in patients with exacerbation of heart failure inadequately responsive to medical therapy: results of the Multicenter Trial of the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM). Circulation 2008, 118:1241–1249.

    Article  PubMed  Google Scholar 

  28. Rose EA, Gelijns AC, Moskowitz AJ, et al.: Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001, 345:1435–1443.

    Article  PubMed  CAS  Google Scholar 

  29. Simon MA, Kormos RL, Murali S, et al.: Myocardial recovery using ventricular assist devices: prevalence, clinical characteristics, and outcomes. Circulation 2005, 112(9 Suppl):I32–I36.

    PubMed  Google Scholar 

  30. Birks EJ, Tansley PD, Hardy J, et al.: Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med 2006, 355:1873–1884.

    Article  PubMed  CAS  Google Scholar 

  31. Maybaum S, Mancini D, Xydas S, et al.: Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD working group. Circulation 2007, 115:2497–2505.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Minnesota, 420 SE Delaware Street, MMC 508, Minneapolis, MN, 55455, USA

    Andrew Boyle

Authors
  1. Andrew Boyle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew Boyle.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boyle, A. Current status of cardiac transplantation and mechanical circulatory support. Curr Heart Fail Rep 6, 28–33 (2009). https://doi.org/10.1007/s11897-009-0006-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-009-0006-8

Keywords

Search

Navigation